1 / 9

Malignant Hyperthermia

Malignant Hyperthermia. By Aaron Denson 1/30/13. Why do Anesthesiologist Care?.

avidan
Download Presentation

Malignant Hyperthermia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Malignant Hyperthermia By Aaron Denson 1/30/13

  2. Why do Anesthesiologist Care? • This rare but life-threatening condition is usually triggered by exposure to certain drugs used for general anesthesia, specifically the volatile anesthetic agents and the neuromuscular blocking agent, succinylcholine.

  3. Mechanism • In 50–70% of cases, malignant hyperthermia is due to a mutation of the ryanodine receptor (type 1), located on the sarcoplasmic reticulum. • This mutation results in a drastic increase in intracellular calcium levels and muscle contraction.

  4. Mechanism (cont’d) • The process of sequestering this excess Ca2+ consumes large amounts of ATP, and generates the hyperthermia that is the hallmark of the disease. • The muscle cell is damaged by depletion of ATP and possibly the high temperatures, and cellular constituents "leak" into the circulation, including K+, myoglobin, creatine, phosphate and creatine kinase.

  5. Signs/Symptoms • Early masseter muscle contracture following administration of succinylcholine, a rise in end-tidal carbon dioxide concentration (despite increased minute ventilation), unexplained tachycardia, and muscle rigidity • Other: Hyperthermia (late), Tachypnea, Acidosis, Rhabdomyolysis • The symptoms usually develop within one hour after exposure to trigger substances, but may even occur several hours later in rare instances

  6. Suceptability testing • The standard procedure is the "caffeine-halothane contracture test", CHCT. • Has a high sensitivity (97 percent) and specificity (78 percent).

  7. Treatment • IV Dantrolene, the only known antidote • Discontinuation of triggering agents • Supportive therapy directed at correcting hyperthermia, acidosis, and organ dysfunction. • Treatment must be instituted rapidly on clinical suspicion of the onset of malignant hyperthermia

  8. Prognosis • In the 1970s, mortality was greater than 80%; with the current management, however, mortality is now less than 5%

  9. Thanks

More Related